A Comprehensive Computational Investigation into the Conserved Virulent Proteins of Shigella species Unveils Potential Small-Interfering RNA Candidates as a New Therapeutic Strategy against Shigellosis

Shigella species account for the second-leading cause of deaths due to diarrheal diseases among children of less than 5 years of age. The emergence of multi-drug-resistant Shigella isolates and the lack of availability of Shigella vaccines have led to the pertinence in the efforts made for the development of new therapeutic strategies against shigellosis. Consequently, designing small-interfering RNA (siRNA) candidates against such infectious agents represents a novel approach to propose new therapeutic candidates to curb the rampant rise of anti-microbial resistance in such pathogens. In this study, we analyzed 264 conserved sequences from 15 different conserved virulence genes of Shigella sp., through extensive rational validation using a plethora of first-generation and second-generation computational algorithms for siRNA designing. Fifty-eight siRNA candidates were obtained by using the first-generation algorithms, out of which only 38 siRNA candidates complied with the second-generation rules of siRNA designing. Further computational validation showed that 16 siRNA candidates were found to have a substantial functional efficiency, out of which 11 siRNA candidates were found to be non-immunogenic. Finally, three siRNA candidates exhibited a sterically feasible three-dimensional structure as exhibited by parameters of nucleic acid geometry such as: the probability of wrong sugar puckers, bad backbone confirmations, bad bonds, and bad angles being within the accepted threshold for stable tertiary structure. Although the findings of our study require further wet-lab validation and optimization for therapeutic use in the treatment of shigellosis, the computationally validated siRNA candidates are expected to suppress the expression of the virulence genes, namely: IpgD (siRNA 9) and OspB (siRNA 15 and siRNA 17) and thus act as a prospective tool in the RNA interference (RNAi) pathway. However, the findings of our study require further wet-lab validation and optimization for regular therapeutic use for treatment of shigellosis.

[1]  P. Sansonetti,et al.  Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study. , 2020, The Lancet. Infectious diseases.

[2]  T. Ahmed,et al.  Exploring novel therapeutic strategies against vivax malaria through an integrated computational investigation to inhibit the merozoite surface protein−1 of Plasmodium vivax , 2020, Informatics in Medicine Unlocked.

[3]  R. Owens,et al.  Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2 , 2020, Nature Structural & Molecular Biology.

[4]  Mohammad Kawsar Sharif Siam,et al.  A computational approach to design potential siRNA molecules as a prospective tool for silencing nucleocapsid phosphoprotein and surface glycoprotein gene of SARS-CoV-2 , 2020, bioRxiv.

[5]  F. Naaz,et al.  Inhibition ofMycobacterium tuberculosis tRNA-LigasesUsing siRNA-Based Gene Silencing Method: A Computational Approach , 2020, J. Comput. Biol..

[6]  S. Shabalina,et al.  Understanding off-target effects through hybridization kinetics and thermodynamics , 2019, Cell Biology and Toxicology.

[7]  A. Cravioto,et al.  How can controlled human infection models accelerate clinical development and policy pathways for vaccines against Shigella? , 2019, Vaccine.

[8]  P. Palit,et al.  A Therapeutic Approach Against Leishmania donovani by Predicting RNAi Molecules Against the Surface Protein, gp63 , 2019, Current Bioinformatics.

[9]  A. Pollard,et al.  Characterization and immunogenicity of a Shigella flexneri 2a O-antigen bioconjugate vaccine candidate , 2019, Glycobiology.

[10]  S. Baker,et al.  Recent insights into Shigella: a major contributor to the global diarrhoeal disease burden , 2018, Current opinion in infectious diseases.

[11]  J. Berkley,et al.  Guidelines for the treatment of dysentery (shigellosis): a systematic review of the evidence , 2018, Paediatrics and international child health.

[12]  J. Platts-Mills,et al.  Shigellosis , 2018, The Lancet.

[13]  P. Newton,et al.  Azithromycin Resistance in Shigella spp. in Southeast Asia , 2018, Antimicrobial Agents and Chemotherapy.

[14]  Christopher J. Williams,et al.  MolProbity: More and better reference data for improved all‐atom structure validation , 2018, Protein science : a publication of the Protein Society.

[15]  S. Willcox,et al.  Shigella species epidemiology and antimicrobial susceptibility: the implications of emerging azithromycin resistance for guiding treatment, guidelines and breakpoints , 2017, The Journal of antimicrobial chemotherapy.

[16]  P. Sansonetti,et al.  The Shigella type III effector IpgD recodes Ca2+ signals during invasion of epithelial cells , 2017, The EMBO journal.

[17]  M. Ebrahimi,et al.  Molecular Mechanisms and Biological Functions of siRNA , 2017, International journal of biomedical science : IJBS.

[18]  Mika Shigematsu,et al.  Estimates of global, regional, and national morbidity, mortality, and aetiologies of diarrhoeal diseases: a systematic analysis for the Global Burden of Disease Study 2015 , 2017, The Lancet. Infectious diseases.

[19]  A. Blocker,et al.  How Do the Virulence Factors of Shigella Work Together to Cause Disease? , 2017, Front. Cell. Infect. Microbiol..

[20]  Paul P. Gardner,et al.  A comprehensive benchmark of RNA–RNA interaction prediction tools for all domains of life , 2016, Bioinform..

[21]  M. Elhefnawi,et al.  In Silico Design and Experimental Validation of siRNAs Targeting Conserved Regions of Multiple Hepatitis C Virus Genotypes , 2016, PloS one.

[22]  Gajendra P. S. Raghava,et al.  Prediction of Immunomodulatory potential of an RNA sequence for designing non-toxic siRNAs and RNA-based vaccine adjuvants , 2016, Scientific Reports.

[23]  S. Baker,et al.  The Rising Dominance of Shigella sonnei: An Intercontinental Shift in the Etiology of Bacillary Dysentery , 2015, PLoS neglected tropical diseases.

[24]  P. Sansonetti,et al.  Escape of Actively Secreting Shigella flexneri from ATG8/LC3-Positive Vacuoles Formed during Cell-To-Cell Spread Is Facilitated by IcsB and VirA , 2015, mBio.

[25]  P. Cossart,et al.  Genome-Wide siRNA Screen Identifies Complementary Signaling Pathways Involved in Listeria Infection and Reveals Different Actin Nucleation Mechanisms during Listeria Cell Invasion and Actin Comet Tail Formation , 2015, mBio.

[26]  A. Bansal,et al.  Co-administration of rIpaB domain of Shigella with rGroEL of S. Typhi enhances the immune responses and protective efficacy against Shigella infection , 2015, Cellular and Molecular Immunology.

[27]  Nalini Singh,et al.  Treatment of drug-resistant Shigella infections , 2015, Expert review of anti-infective therapy.

[28]  T. Farag,et al.  Shigella Isolates From the Global Enteric Multicenter Study Inform Vaccine Development , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  A. Maurelli,et al.  Potential Novel Antibiotics from HTS Targeting the Virulence-regulating Transcription Factor, VirF, from Shigella flexneri , 2014, The Journal of Antibiotics.

[30]  A. Faruque,et al.  Changing Trends in the Prevalence of Shigella Species: Emergence of Multi-Drug Resistant Shigella sonnei Biotype g in Bangladesh , 2013, PloS one.

[31]  W. Picking,et al.  Characterization of a Novel Fusion Protein from IpaB and IpaD of Shigella spp. and Its Potential as a Pan-Shigella Vaccine , 2013, Infection and Immunity.

[32]  D. Monack,et al.  Newly described pattern recognition receptors team up against intracellular pathogens , 2013, Nature Reviews Immunology.

[33]  Chao Zhang,et al.  Influence of mRNA Features on siRNA Interference Efficacy , 2013, J. Bioinform. Comput. Biol..

[34]  J. Clements,et al.  Evaluation of immunogenicity and protective efficacy of orally delivered Shigella type III secretion system proteins IpaB and IpaD. , 2013, Vaccine.

[35]  M. Levine,et al.  Progress and pitfalls in Shigella vaccine research , 2013, Nature Reviews Gastroenterology &Hepatology.

[36]  J. Irache,et al.  Recent progress towards development of a Shigella vaccine , 2013, Expert review of vaccines.

[37]  R. Valdivia,et al.  Human Genome-Wide RNAi Screen for Host Factors That Modulate Intracellular Salmonella Growth , 2012, PloS one.

[38]  Jacek Blazewicz,et al.  Automated 3D structure composition for large RNAs , 2012, Nucleic acids research.

[39]  Monir Hajiaghayi,et al.  Analysis of energy-based algorithms for RNA secondary structure prediction , 2012, BMC Bioinformatics.

[40]  J. Clements,et al.  Broadly Protective Shigella Vaccine Based on Type III Secretion Apparatus Proteins , 2011, Infection and Immunity.

[41]  Feng Ding,et al.  On the significance of an RNA tertiary structure prediction. , 2010, RNA.

[42]  David H. Mathews,et al.  RNAstructure: software for RNA secondary structure prediction and analysis , 2010, BMC Bioinformatics.

[43]  J. Farrar,et al.  A changing picture of shigellosis in southern Vietnam: shifting species dominance, antimicrobial susceptibility and clinical presentation , 2009, BMC infectious diseases.

[44]  Shinichi Morishita,et al.  siDirect 2.0: updated software for designing functional siRNA with reduced seed-dependent off-target effect , 2009, BMC Bioinformatics.

[45]  Daniel G. Anderson,et al.  Knocking down barriers: advances in siRNA delivery , 2009, Nature Reviews Drug Discovery.

[46]  C. Parsot,et al.  MxiC is secreted by and controls the substrate specificity of the Shigella flexneri type III secretion apparatus , 2009, Molecular microbiology.

[47]  A. Maurelli,et al.  Shigella flexneri type III secretion system effectors OspB and OspF target the nucleus to downregulate the host inflammatory response via interactions with retinoblastoma protein , 2009, Molecular microbiology.

[48]  F. Aarestrup,et al.  Shigella from humans in Thailand during 1993 to 2006: spatial-time trends in species and serotype distribution. , 2008, Foodborne pathogens and disease.

[49]  M. Goldberg,et al.  Structural and functional studies indicate that Shigella VirA is not a protease and does not directly destabilize microtubules. , 2008, Biochemistry.

[50]  David H. Mathews,et al.  OligoWalk: an online siRNA design tool utilizing hybridization thermodynamics , 2008, Nucleic Acids Res..

[51]  Stefan L Ameres,et al.  The impact of target site accessibility on the design of effective siRNAs , 2008, Nature Biotechnology.

[52]  Mark Johnson,et al.  NCBI BLAST: a better web interface , 2008, Nucleic Acids Res..

[53]  David H. Mathews,et al.  Efficient siRNA selection using hybridization thermodynamics , 2007, Nucleic acids research.

[54]  Chi Yu Chan,et al.  Effect of target secondary structure on RNAi efficiency. , 2007, RNA.

[55]  M. Ichihara,et al.  Thermodynamic instability of siRNA duplex is a prerequisite for dependable prediction of siRNA activities , 2007, Nucleic acids research.

[56]  Jack Snoeyink,et al.  Nucleic Acids Research Advance Access published April 22, 2007 MolProbity: all-atom contacts and structure validation for proteins and nucleic acids , 2007 .

[57]  Warren A. Kibbe,et al.  The issue of amalgams. , 1996, Nucleic Acids Res..

[58]  P. Sansonetti,et al.  Shigella’s ways of manipulating the host intestinal innate and adaptive immune system: a tool box for survival? , 2007, Immunology and cell biology.

[59]  T. Katoh,et al.  Specific residues at every third position of siRNA shape its efficient RNAi activity , 2007, Nucleic acids research.

[60]  T. Tuschl,et al.  On the art of identifying effective and specific siRNAs , 2006, Nature Methods.

[61]  Anastasia Khvorova,et al.  Off-target effects by siRNA can induce toxic phenotype. , 2006, RNA.

[62]  Peter F. Stadler,et al.  Thermodynamics of RNA-RNA Binding , 2006, German Conference on Bioinformatics.

[63]  B. Nawrot,et al.  Chemical and structural diversity of siRNA molecules. , 2006, Current topics in medicinal chemistry.

[64]  Peter F. Stadler,et al.  Partition function and base pairing probabilities of RNA heterodimers , 2006, Algorithms for Molecular Biology.

[65]  L. R. Livingstone,et al.  Criteria for effective design, construction, and gene knockdown by shRNA vectors , 2006, BMC biotechnology.

[66]  Pierre Legrain,et al.  The Shigella flexneri effector OspG interferes with innate immune responses by targeting ubiquitin-conjugating enzymes. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[67]  D. Turner.  Faculty Opinions recommendation of RNA secondary structure prediction by centroids in a Boltzmann weighted ensemble. , 2005 .

[68]  C. Lawrence,et al.  RNA secondary structure prediction by centroids in a Boltzmann weighted ensemble. , 2005, RNA.

[69]  Dieter Huesken,et al.  Design of a genome-wide siRNA library using an artificial neural network , 2005, Nature Biotechnology.

[70]  David H. Mathews,et al.  Predicting a set of minimal free energy RNA secondary structures common to two sequences , 2005, Bioinform..

[71]  H. Soifer,et al.  siRNA target site secondary structure predictions using local stable substructures , 2005, Nucleic acids research.

[72]  A. Konagaya,et al.  An Effective Method for Selecting siRNA Target Sequences in Mammalian Cells , 2004, Cell cycle.

[73]  A. Reynolds,et al.  Rational siRNA design for RNA interference , 2004, Nature Biotechnology.

[74]  M. Levine,et al.  Phase I Evaluation of ΔvirG Shigella sonnei Live, Attenuated, Oral Vaccine Strain WRSS1 in Healthy Adults , 2002, Infection and Immunity.

[75]  A. Maurelli,et al.  Spa33, a Cell Surface-Associated Subunit of the Mxi-Spa Type III Secretory Pathway of Shigella flexneri, Regulates Ipa Protein Traffic , 2001, Infection and Immunity.

[76]  P. Sansonetti,et al.  IpgD, a protein secreted by the type III secretion machinery of Shigella flexneri, is chaperoned by IpgE and implicated in entry focus formation , 2000, Molecular microbiology.

[77]  S. Freier,et al.  Effects of RNA secondary structure on cellular antisense activity. , 2000, Nucleic acids research.

[78]  Stephen A. Krawetz,et al.  Bioinformatics Methods and Protocols , 1999 .

[79]  J. Shiloach,et al.  Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoids , 1993, Infection and immunity.

[80]  C. Hoge,et al.  Ciprofloxacin and Loperamide in the Treatment of Bacillary Dysentery , 1993, Annals of Internal Medicine.

[81]  C. Sasakawa,et al.  Temperature‐regulated expression of invasion genes in Shigella flexneri is controlled through the transcriptional activation of the virB gene on the large plasmid , 1991, Molecular microbiology.

[82]  M. Riddle.  Is a Shigella vaccine needed for travellers and the military? , 2018, Journal of travel medicine.

[83]  Tomasz Zok,et al.  New functionality of RNAComposer: an application to shape the axis of miR160 precursor structure. , 2016, Acta biochimica Polonica.

[84]  Jacek Blazewicz,et al.  Automated RNA 3D Structure Prediction with RNAComposer. , 2016, Methods in molecular biology.

[85]  Fabian Sievers,et al.  Clustal Omega, accurate alignment of very large numbers of sequences. , 2014, Methods in molecular biology.

[86]  K. Ui-Tei,et al.  Designing functional siRNA with reduced off-target effects. , 2013, Methods in molecular biology.

[87]  David H Mathews,et al.  RNA structure prediction: an overview of methods. , 2012, Methods in molecular biology.

[88]  P. Linsley,et al.  Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application , 2010, Nature Reviews Drug Discovery.

[89]  D. Mathews.  Using OligoWalk to identify efficient siRNA sequences. , 2010, Methods in molecular biology.

[90]  C. Sasakawa,et al.  Shigella IpgB1 promotes bacterial entry through the ELMO–Dock180 machinery , 2007, Nature Cell Biology.

[91]  J. G. Patton,et al.  siRNA therapeutics: big potential from small RNAs , 2005, Gene Therapy.

[92]  C. Sasakawa,et al.  Temperature-regulated expression of invasion genes in Shigella flexneri is controlled through the transcriptional activation of the virB gene on the large plasmid. , 1991, Molecular microbiology.